CoChat
Sign Up
Cited by 6Bone health and osteoporosis researchBone health and treatmentsBone Metabolism and Diseases

Bisphosphonates and glucocorticoid osteoporosis in men: results of a randomized controlled trial comparing zoledronic acid with risedronate

Sambrook, Philip N., Roux, Christian, Devogelaer, Jean-Pierre, Saag, Kenneth, Lau, Chak-Sing, Reginster, Jean-Yves, Bucci-Rechtweg, Christina, Su, Guoqin +1 more·2012·Bone
DOI 10.1016/j.bone.2011.10.024
Open this paper in CoChat — free account

Abstract

Background We studied 265 men (mean age 56.4 years; range 18-83 years), among patients enrolled in two arms of a double-blind, 1-year study comparing the effects of zoledronic acid (ZOL) with risedronate (RIS) in patients either commencing (prednisolone 7.5 mg/day or equivalent) (prevention arm, n=88) or continuing glucocorticoid therapy (treatment arm, n=177).Methods Patients received either a single ZOL 5 mg infusion or RIS 5 mg oral daily at randomization, along with calcium (1000 mg) and vitamin D (400-1200 IU). Primary endpoint: difference in percentage change from baseline in bone mineral density (BMD) at the lumbar spine (LS) at 12 months. Secondary endpoints: percentage changes in BMD at total hip (TH) and femoral neck (FN), relative changes in bone turnover markers (β-CTx and P1NP), and overall safety.Findings In the treatment subpopulation, ZOL increased LS BMD by 4.7% vs. 3.3% for RIS and at TH the percentage changes were 1.8% vs. 0.2%, respectively. In the prevention subpopulation, bone loss was prevented by both treatments. At LS the percentage changes were 2.5% vs. -0.2% for ZOL vs. RIS and at TH the percentage changes were 1.1% vs. -0.4%, respectively. ZOL significantly increased lumbar spine BMD more than RIS at Month 12 in both the prevention population (p=0.0024) and the treatment subpopulation (p=0.0232) in men. In the treatment subpopulation, ZOL demonstrated a significantly greater reduction in serum β-CTx and P1NP relative to RIS at all time-points. In the prevention subpopulation, ZOL significantly reduced β-CTx at all time-points, and P1NP at Month 3 (p=0.0297) only. Both treatments were well tolerated in men, albeit with a higher incidence of influenza-like illness and pyrexia events post-infusion with ZOL.Interpretation Once-yearly ZOL preserves or increases BMD within 1 year to a greater extent than daily RIS in men receiving glucocorticoid therapy.

Integrity signals

Registry

Crossref · 10.1016/j.bone.2011.10.024

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In clinical practice, both bisphosphonates and PTH increase spine BMD to a greater extent than hip BMD.

    “In clinical practice, both bisphosphonates and PTH increase the spine BMD to a greater extent than the hip BMD [12, 14, 47, 50-53].”

    From Prevention of glucocorticoid induced bone changes with beta-ecdysone (2015) · cites this paper as [53]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Sambrook, P. N., Roux, C., Devogelaer, J.-P., Saag, K., Lau, C.-S., Reginster, J.-Y., Bucci-Rechtweg, C., Su, G., & Reid, D. M.
Affiliations
  • The University of Sydney (AU)
  • Université Paris Descartes (FR)
  • UCLouvain (BE)
  • University of Alabama at Birmingham (US)
  • University of Dundee (GB)
  • University of Liège (BE)
  • University of Aberdeen (GB)
Corresponding author
Sambrook, Philip N.
ORCID
Venue
Bone
Publisher
Elsevier BV
Published
2012-01
Volume
50
Issue
1
Pages
289-295
ISSN
  • 1873-2763 (ISSN-L)
  • 8756-3282
DOI
10.1016/j.bone.2011.10.024
OpenAlex
W1545053868
Cited by
3
References
40
Citations by year
2020: 1 · 2014: 1 · 2012: 1
FWCI
0.68
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Bone (publishedVersion)
  • PubMed (publishedVersion)
  • Digital Access to Libraries (submittedVersion)
  • Digital Access to Libraries (Université catholique de Louvain (UCL), l'Université de Namur (UNamur) and the Université Saint-Louis (USL-B)) (submittedVersion)
  • ORBi (University of Liège) (submittedVersion)
  • Osteoporosis International
Funders
Novartis
Topics
  • Health Sciences › Medicine › Orthopedics and Sports Medicine › Bone health and osteoporosis research
  • Health Sciences › Medicine › Oncology › Bone health and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
Keywords
glucocorticoid-induced osteoporosis, zoledronic acid, risedronate, bisphosphonates, men, bone mineral density, prednisolone, bone turnover markers, bone resorption, femoral neck, lumbar spine, total hip, drug safety, influenza-like illness, fever, calcium and vitamin D supplementation
MeSH terms
Risedronic Acid, Zoledronic Acid, Adolescent, Adult, Aged, Aged, 80 and over, Diphosphonates, Double-Blind Method, Femur Neck, Glucocorticoids, Hip Joint, Humans, Imidazoles, Lumbar Vertebrae, Male, Middle Aged, Osteoporosis, Etidronic Acid, Bone Density, Bone Density Conservation Agents, Young Adult

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review